{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T19:23:46Z","timestamp":1793733826335,"version":"4.6.1"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,5,3]],"date-time":"2023-05-03T00:00:00Z","timestamp":1683072000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,5,3]],"date-time":"2023-05-03T00:00:00Z","timestamp":1683072000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Adjuvant trastuzumab in HER2+\u2009breast cancer reduces recurrence and mortality, and has been the standard treatment since 2006. The objective was to analyze health outcomes in the real world. Observational, retrospective study of patients with HER2+\u2009breast cancer, stages I\u2013III, treated with adjuvant trastuzumab in the past 15\u00a0years in only one center and for the first time in Spain. Survival was analyzed according to the number of cycles and cardiotoxicity. Two hundred and seventy-five HER2positive patients (18.60%) out of 1479 received adjuvant (73%) or neoadjuvant\/adjuvant (26%) trastuzumab, concomitantly (90%) or sequentially (10%) with chemotherapy. The probability of overall and disease-free survival (OS and DFS) at 5\u00a0years was 0.93 (95% CI 0.89\u20130.96), and 0.88 (95% CI 0.83\u20130.92). The number of cases with a significant and asymptomatic\u00a0decrease in ventricular ejection fraction and heart failure were 54 (19.64%) and 12 (4.36%), respectively. Sixty-eight patients (24.70%) received 16 or fewer cycles, especially those older than 65 (OR 0.371, 95% CI 0.152\u20130.903; p\u2009=\u20090.029) and with cardiotoxicity (OR 15.02, 95% CI 7.437\u201330.335; p\u2009&lt;\u20090.001). The risk of cardiotoxicity was associated with having received radiotherapy (OR 0.0362, 95% CI 0.139\u20130.938; p\u2009=\u20090.037). Arterial hypertension (HR 0.361, 95% CI 0.151\u20130.863, p\u2009=\u20090.022), neoadjuvant treatment (HR 0.314, 95% CI 0.132\u20130.750, p\u2009=\u20090.009) and cardiotoxicity (HR 2.755, 95% CI 1.235\u20136.143, p\u2009=\u20090.013) maintained significant association with OS. Only neoadjuvant treatment maintained a significant association with DFS (HR 0.437, 95% CI 0.213\u20130.899, p\u2009=\u20090.024). The effectiveness of neoadjuvant and adjuvant trastuzumab can be considered comparable to those of clinical trials. In the real world, factors such as age, hypertension, radiotherapy, neoadjuvant treatment, and cardiotoxicity should be taken into consideration to optimize outcomes.<\/jats:p>","DOI":"10.1038\/s41598-023-34429-9","type":"journal-article","created":{"date-parts":[[2023,5,3]],"date-time":"2023-05-03T10:02:25Z","timestamp":1683108145000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Real world evidence of adjuvant trastuzumab in HER2 positive early breast cancer"],"prefix":"10.1038","volume":"13","author":[{"given":"J.","family":"Lluch-G\u00f3mez","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V.","family":"N\u00fa\u00f1ez-\u00c1lvarez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"de la Torre-Hita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Bernal-G\u00f3mez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Campini-Bermejo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"Perdomo-Zald\u00edvar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"Rodr\u00edguez-P\u00e9rez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Calvete-Candenas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M. J.","family":"Mart\u00ednez-Bautista","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"Ben\u00edtez-Rodr\u00edguez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8403-9804","authenticated-orcid":false,"given":"J. M.","family":"Baena-Ca\u00f1ada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,5,3]]},"reference":[{"issue":"22","key":"34429_CR1","doi-asserted-by":"publisher","first-page":"10578","DOI":"10.1073\/pnas.89.22.10578","volume":"89","author":"CT Guy","year":"1992","unstructured":"Guy, C. T. et al. Expression of the neu protooncogene in the mammary epithelium of transgenic mice induces metastatic disease. Proc. Natl. Acad. Sci. U. S. A. 89(22), 10578\u201310582. https:\/\/doi.org\/10.1073\/pnas.89.22.10578 (1992).","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"34429_CR2","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1126\/science.3798106","volume":"235","author":"DJ Slamon","year":"1987","unstructured":"Slamon, D. J. et al. Human breast cancer: Correlation of relapse and survival with amplification of the HER-2\/neu oncogene. Science 235, 177\u2013182. https:\/\/doi.org\/10.1126\/science.3798106 (1987).","journal-title":"Science"},{"key":"34429_CR3","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1126\/science.2470152","volume":"244","author":"DJ Slamon","year":"1989","unstructured":"Slamon, D. J. et al. Studies of the HER-2\/neu proto-oncogene in human breast and ovarian cancer. Science 244, 707\u2013712. https:\/\/doi.org\/10.1126\/science.2470152 (1989).","journal-title":"Science"},{"key":"34429_CR4","doi-asserted-by":"publisher","first-page":"346","DOI":"10.1038\/nature10983","volume":"486","author":"C Curtis","year":"2012","unstructured":"Curtis, C. et al. The genomic and transcriptomic architecture of 2,000 breast tumours reveals novel subgroups. Nature 486, 346\u2013352. https:\/\/doi.org\/10.1038\/nature10983 (2012).","journal-title":"Nature"},{"key":"34429_CR5","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1038\/emboj.2013.19","volume":"23","author":"CH Yeon","year":"2005","unstructured":"Yeon, C. H. & Pegram, M. D. Anti-erbB-2 antibody trastuzumab in the treatment of HER2-amplified breast cancer. Invest. New Drugs. 23, 391\u2013409. https:\/\/doi.org\/10.1038\/emboj.2013.19 (2005).","journal-title":"Invest. New Drugs."},{"key":"34429_CR6","doi-asserted-by":"publisher","first-page":"1659","DOI":"10.1056\/NEJMoa052306","volume":"353","author":"MJ Piccart-Gebhart","year":"2005","unstructured":"Piccart-Gebhart, M. J. et al. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N. Engl. J. Med. 353, 1659\u20131672. https:\/\/doi.org\/10.1056\/NEJMoa052306 (2005).","journal-title":"N. Engl. J. Med."},{"key":"34429_CR7","doi-asserted-by":"publisher","first-page":"1673","DOI":"10.1056\/NEJMoa052122","volume":"353","author":"EH Romond","year":"2005","unstructured":"Romond, E. H. et al. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N. Engl. J. Med. 353, 1673\u20131684. https:\/\/doi.org\/10.1056\/NEJMoa052122 (2005).","journal-title":"N. Engl. J. Med."},{"key":"34429_CR8","doi-asserted-by":"publisher","first-page":"1273","DOI":"10.1056\/NEJMoa0910383","volume":"365","author":"D Slamon","year":"2011","unstructured":"Slamon, D. et al. Adjuvant trastuzumab in HER2-positive breast cancer. N. Engl. J. Med. 365, 1273\u20131283. https:\/\/doi.org\/10.1056\/NEJMoa0910383 (2011).","journal-title":"N. Engl. J. Med."},{"key":"34429_CR9","doi-asserted-by":"publisher","first-page":"2328","DOI":"10.1093\/annonc\/mdy414","volume":"29","author":"P Conte","year":"2018","unstructured":"Conte, P. et al. Nine weeks versus 1 year adjuvant trastuzumab in combination with chemotherapy: Final results of the phase III randomized Short-HER study. Ann. Oncol. 29, 2328\u20132333 (2018).","journal-title":"Ann. Oncol."},{"key":"34429_CR10","doi-asserted-by":"publisher","first-page":"1199","DOI":"10.1001\/jamaoncol.2018.1380","volume":"4","author":"H Joensuu","year":"2018","unstructured":"Joensuu, H. et al. Effect of adjuvant trastuzumab for a duration of 9 weeks vs. 1 year with concomitant chemotherapy for early human epidermal growth factor receptor 2-positive breast cancer. JAMA Oncol. 4, 1199\u20131206 (2018).","journal-title":"JAMA Oncol."},{"key":"34429_CR11","doi-asserted-by":"publisher","first-page":"1333","DOI":"10.1093\/annonc\/mdv213","volume":"26","author":"D Mavroudis","year":"2015","unstructured":"Mavroudis, D. et al. Six versus 12 months of adjuvant trastuzumab in combination with dose-dense chemotherapy for women with HER2-positive breast cancer: A multicenter randomized study by the Hellenic Oncology Research Group (HORG). Ann. Oncol. 26, 1333\u20131340 (2015).","journal-title":"Ann. Oncol."},{"key":"34429_CR12","doi-asserted-by":"publisher","first-page":"2599","DOI":"10.1016\/S0140-6736(19)30650-6","volume":"393","author":"HM Earl","year":"2019","unstructured":"Earl, H. M. et al. 6 vs. 12 months of adjuvant trastuzumab for HER2-positive early breast cancer (PERSEPHONE): 4-year disease-free survival results of a randomised phase 3 non-inferiority trial. Lancet 393, 2599\u20132612 (2019).","journal-title":"Lancet"},{"key":"34429_CR13","doi-asserted-by":"publisher","first-page":"2591","DOI":"10.1016\/S0140-6736(19)30653-1","volume":"393","author":"X Pivot","year":"2019","unstructured":"Pivot, X. et al. 6 months versus 12 months of adjuvant trastuzumab in early breast cancer (PHARE): Final analysis of a multicentre, open-label, phase 3 randomised trial. Lancet 393, 2591\u20132598 (2019).","journal-title":"Lancet"},{"key":"34429_CR14","doi-asserted-by":"publisher","first-page":"pkz033","DOI":"10.1093\/jncics\/pkz033","volume":"3","author":"H Goldvaser","year":"2019","unstructured":"Goldvaser, H. et al. Deescalating adjuvant trastuzumab in HER2-Positive early-stage breast cancer: A systemic review and meta-analysis. JNCI Cancer Spectr. 3, pkz033. https:\/\/doi.org\/10.1093\/jncics\/pkz033 (2019).","journal-title":"JNCI Cancer Spectr."},{"issue":"1","key":"34429_CR15","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1007\/s10549-021-06280-x","volume":"188","author":"N Dempsey","year":"2021","unstructured":"Dempsey, N. et al. Trastuzumab-induced cardiotoxicity: A review of clinical risk factors, pharmacologic prevention, and cardiotoxicity of other HER2-directed therapies. Breast Cancer Res. Treat. 188(1), 21\u201336. https:\/\/doi.org\/10.1007\/s10549-021-06280-x (2021).","journal-title":"Breast Cancer Res. Treat."},{"issue":"2","key":"34429_CR16","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1016\/j.annonc.2019.10.023","volume":"31","author":"G Curigliano","year":"2021","unstructured":"Curigliano, G. et al. Management of cardiac disease in cancer patients throughout oncological treatment: ESMO consensus recommendations. Ann. Oncol. 31(2), 171\u2013190. https:\/\/doi.org\/10.1016\/j.annonc.2019.10.023 (2021).","journal-title":"Ann. Oncol."},{"key":"34429_CR17","doi-asserted-by":"publisher","first-page":"1139","DOI":"10.1016\/S1470-2045(21)00288-6","volume":"22","author":"Early Breast Cancer Trialists\u2019 Collaborative group (EBCTCG)","year":"2021","unstructured":"Early Breast Cancer Trialists\u2019 Collaborative group (EBCTCG). Trastuzumab for early-stage, HER2-positive breast cancer: A meta-analysis of 13 864 women in seven randomised trials. Lancet Oncol. 22, 1139\u20131150. https:\/\/doi.org\/10.1016\/S1470-2045(21)00288-6 (2021).","journal-title":"Lancet Oncol."},{"key":"34429_CR18","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1016\/S0140-6736(09)61964-4","volume":"375","author":"L Gianni","year":"2010","unstructured":"Gianni, L. et al. Neoadjuvant chemotherapy with trastuzumab followed by adjuvant trastuzumab versus neoadjuvant chemotherapy alone, in patients with HER2-positive locally advanced breast cancer (the NOAH trial): A randomised controlled superiority trial with a parallel HER2-negative cohort. Lancet 375, 377\u2013384. https:\/\/doi.org\/10.1016\/S0140-6736(09)61964-4 (2010).","journal-title":"Lancet"},{"key":"34429_CR19","doi-asserted-by":"publisher","first-page":"2015","DOI":"10.1200\/JCO.2009.23.8303","volume":"28","author":"G von Minckwitz","year":"2010","unstructured":"von Minckwitz, G. et al. Capecitabine in addition to anthracycline- and taxane-based neoadjuvant treatment in patients with primary breast cancer: Phase III GeparQuattro study. J. Clin. Oncol. 28, 2015\u20132023. https:\/\/doi.org\/10.1200\/JCO.2009.23.8303 (2010).","journal-title":"J. Clin. Oncol."},{"key":"34429_CR20","doi-asserted-by":"publisher","first-page":"1317","DOI":"10.1016\/S1470-2045(13)70502-3","volume":"14","author":"AU Buzdar","year":"2013","unstructured":"Buzdar, A. U. et al. Fluorouracil, epirubicin, and cyclophosphamide (FEC-75) followed by paclitaxel plus trastuzumab versus paclitaxel plus trastuzumab followed by FEC-75 plus trastuzumab as neoadjuvant treatment for patients with HER2-positive breast cancer (Z1041): A randomised, controlled, phase 3 trial. Lancet Oncol. 14, 1317\u20131325. https:\/\/doi.org\/10.1016\/S1470-2045(13)70502-3 (2013).","journal-title":"Lancet Oncol."},{"key":"34429_CR21","doi-asserted-by":"publisher","first-page":"3525","DOI":"10.1200\/JCO.2007.11.0106","volume":"25","author":"ML Telli","year":"2007","unstructured":"Telli, M. L., Hunt, S. A., Carlson, R. W. & Guardino, A. E. Trastuzumab-related cardiotoxicity: Calling into question the concept of reversibility. J. Clin. Oncol. 25, 3525\u20133533. https:\/\/doi.org\/10.1200\/JCO.2007.11.0106 (2007).","journal-title":"J. Clin. Oncol."},{"issue":"16","key":"34429_CR22","doi-asserted-by":"publisher","first-page":"2638","DOI":"10.1200\/JCO.2008.17.9549","volume":"27","author":"MY Halyard","year":"2009","unstructured":"Halyard, M. Y. et al. Radiotherapy and adjuvant trastuzumab in operable breast cancer: Tolerability and adverse event data from the NCCTG Phase III Trial N9831. J. Clin. Oncol. 27(16), 2638\u20132644. https:\/\/doi.org\/10.1200\/JCO.2008.17.9549 (2009).","journal-title":"J. Clin. Oncol."},{"key":"34429_CR23","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1186\/1471-2407-7-153","volume":"7","author":"GA Viani","year":"2007","unstructured":"Viani, G. A., Afonso, S. L., Stefano, E. J., De Fendi, L. I. & Soares, F. V. Adjuvant trastuzumab in the treatment of her-2-positive early breast cancer: A meta-analysis of published randomized trials. BMC Cancer 7, 153. https:\/\/doi.org\/10.1186\/1471-2407-7-153 (2007).","journal-title":"BMC Cancer"},{"issue":"2","key":"34429_CR24","doi-asserted-by":"publisher","first-page":"e235","DOI":"10.1200\/OP.21.00274","volume":"18","author":"R Gidwani","year":"2022","unstructured":"Gidwani, R. et al. Survival in the real world: A national analysis of patients treated for early-stage breast cancer. JCO Oncol. Pract. 18(2), e235\u2013e249. https:\/\/doi.org\/10.1200\/OP.21.00274 (2022).","journal-title":"JCO Oncol. Pract."},{"key":"34429_CR25","doi-asserted-by":"publisher","first-page":"S1283","DOI":"10.1016\/annonc\/annonc741","volume":"32","author":"HM Earl","year":"2021","unstructured":"Earl, H. M. et al. Individual patient data meta-analysis of 5 non-inferiority RCTs of reduced duration single agent adjuvant trastuzumab in the treatment of HER2-positive early breast cancer. Ann. Oncol. 32, S1283\u2013S1346. https:\/\/doi.org\/10.1016\/annonc\/annonc741 (2021).","journal-title":"Ann. Oncol."},{"issue":"12","key":"34429_CR26","doi-asserted-by":"publisher","first-page":"1222","DOI":"10.1093\/jnci\/djaa054","volume":"112","author":"M Rushton","year":"2020","unstructured":"Rushton, M. et al. Impact of stopping trastuzumab in early breast cancer: A population-based study in Ontario, Canada. J. Natl. Cancer Inst. 112(12), 1222\u20131230. https:\/\/doi.org\/10.1093\/jnci\/djaa054 (2020).","journal-title":"J. Natl. Cancer Inst."},{"issue":"11","key":"34429_CR27","doi-asserted-by":"publisher","first-page":"13209","DOI":"10.18632\/oncotarget.4801","volume":"7","author":"C Palmieri","year":"2016","unstructured":"Palmieri, C. et al. Neoadjuvant chemotherapy and trastuzumab versus neoadjuvant chemotherapy followed by post-operative trastuzumab for patients with HER2-positive breast cancer. Oncotarget 7(11), 13209\u201313220. https:\/\/doi.org\/10.18632\/oncotarget.4801 (2016).","journal-title":"Oncotarget"},{"key":"34429_CR28","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1097\/00000421-198212000-00014","volume":"5","author":"MM Oken","year":"1982","unstructured":"Oken, M. M. et al. Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am. J. Clin. Oncol. 5, 649\u2013655 (1982).","journal-title":"Am. J. Clin. Oncol."},{"key":"34429_CR29","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1016\/0021-9681(87)90171-8","volume":"40","author":"ME Charlson","year":"1987","unstructured":"Charlson, M. E., Pompei, P., Ales, K. L. & MacKenzie, C. R. A new method of classifying prognostic comorbidity in longitudinal studies: Development and validation. J. Chron. Dis. 40, 373\u2013383. https:\/\/doi.org\/10.1016\/0021-9681(87)90171-8 (1987).","journal-title":"J. Chron. Dis."},{"key":"34429_CR30","doi-asserted-by":"publisher","first-page":"2127","DOI":"10.1200\/JCO.2006.10.3523","volume":"25","author":"CA Hudis","year":"2007","unstructured":"Hudis, C. A. et al. Proposal for standardized definitions for efficacy end points in adjuvant breast cancer trials: The STEEP system. J. Clin. Oncol. 25, 2127\u20132132. https:\/\/doi.org\/10.1200\/JCO.2006.10.3523 (2007).","journal-title":"J. Clin. Oncol."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-023-34429-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-023-34429-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-023-34429-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,3]],"date-time":"2023-05-03T10:14:01Z","timestamp":1683108841000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-023-34429-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5,3]]},"references-count":30,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["34429"],"URL":"https:\/\/doi.org\/10.1038\/s41598-023-34429-9","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,5,3]]},"assertion":[{"value":"11 August 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 April 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 May 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"7168"}}